Covid-19 roundup: AstraZeneca's Farxiga fails PhIII test; Supply deal for Eli Lilly's solo bamlanivimab officially canceled
Around the same time AstraZeneca struck up a vaccine partnership with Oxford last April, the pharma giant also put together a game plan to develop treatments — both new and repurposed — for Covid-19. One of them has now ended in failure.
The Phase III DARE-19 trial recruited 1,250 patients hospitalized with Covid-19 over the past year and gave half of them the diabetes drug Farxiga on top of standard of care therapy.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
